8COH
| Structure of the complement C5 specific nanobody TPP-3444 | Descriptor: | CITRIC ACID, MANGANESE (II) ION, Nanobody TPP-3444 | Authors: | Pedersen, D.V, Andersen, G.R. | Deposit date: | 2023-02-28 | Release date: | 2024-01-03 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol.Immunol., 165, 2023
|
|
6RUR
| Structure of the SCIN stabilized C3bBb convertase bound to properdin | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Complement C3, ... | Authors: | Pedersen, D.V, Gadeberg, T.A.F, Andersen, G.R. | Deposit date: | 2019-05-29 | Release date: | 2019-08-21 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (6 Å) | Cite: | Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front Immunol, 10, 2019
|
|
6RV6
| Structure of properdin lacking TSR3 based on anomalous data | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Properdin, alpha-D-mannopyranose, ... | Authors: | Pedersen, D.V, Andersen, G.R. | Deposit date: | 2019-05-31 | Release date: | 2019-08-21 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (3.507 Å) | Cite: | Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front Immunol, 10, 2019
|
|
6SEJ
| Structure of a functional monomeric properdin lacking TSR3 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Properdin, alpha-D-mannopyranose, ... | Authors: | Pedersen, D.V, Andersen, G.R. | Deposit date: | 2019-07-30 | Release date: | 2019-08-21 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (3.501 Å) | Cite: | Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front Immunol, 10, 2019
|
|
6RUS
| Structure of a functional properdin monomer | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Properdin, SULFATE ION, ... | Authors: | Pedersen, D.V, Andersen, G.R. | Deposit date: | 2019-05-29 | Release date: | 2019-08-21 | Last modified: | 2024-05-01 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front Immunol, 10, 2019
|
|
6RUV
| |
7NOZ
| Structure of the nanobody stablized properdin bound alternative pathway proconvertase C3b:FB:FP | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Complement C3 alpha chain, Complement C3 beta chain, ... | Authors: | Lorenzen, J, Pedersen, D.V, Andersen, G.R. | Deposit date: | 2021-02-26 | Release date: | 2022-07-27 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (3.9 Å) | Cite: | Structure determination of an unstable macromolecular complex enabled by nanobody-peptide bridging. Protein Sci., 31, 2022
|
|
8Q78
| |
8Q6R
| Structure of complement FP in complex with the TPP-3077 VHH | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCOCHOLIC ACID, ... | Authors: | Andersen, G.R, Pedersen, D.V. | Deposit date: | 2023-08-14 | Release date: | 2024-08-28 | Last modified: | 2024-10-09 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structure of complement FP in complex with the TPP-3077 VHH To Be Published
|
|
8COE
| complement C5 in complex with the LCP0195 nanobody | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Complement C5 alpha chain, Complement C5 beta chain, ... | Authors: | Andersen, G.R, Pedersen, D.V. | Deposit date: | 2023-02-28 | Release date: | 2024-01-03 | Method: | X-RAY DIFFRACTION (4.2 Å) | Cite: | Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration. Mol.Immunol., 165, 2023
|
|
6RU3
| |